The US Food and Drug Administration (FDA) published a much-anticipated draft guidance that recommends more diverse patient cohorts in clinical trials and is meant to improve the data the agency ...
With an eye toward reducing review cycles for abbreviated new drug applications (ANDAs) and better informing industry of the roles and responsibilities of US Food and Drug Administration (FDA) review ...
The new action plan — SAPCC 2.0 — replaces the existing 2019 plan, which uses older datasets and is less relevant for current weather patterns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results